Macroagregados De Albúmina Humana Curium (Human Albumin As Macroaggregates)

The macroaggregates add colloidal protein to the bloodstream, raising plasma oncotic pressure. This draws fluid from the interstitial space into the vascular compartment, expanding circulating volume and supporting blood pressure and tissue perfusion.

The appropriate dose is determined by the prescribing clinician based on the patient’s clinical condition, weight, and laboratory values. Dosing is individualized and administered intravenously under medical supervision.

Safety data for human albumin macroaggregates in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Human albumin macroaggregates are a natural plasma protein, offering oncotic support without the synthetic components found in some colloids. Compared with crystalloids, they provide more sustained volume expansion, while compared with other albumin solutions they are presented as macroaggregates, which may affect distribution and clearance characteristics.

Store the product at 2‑8 °C, protected from light. Keep it in the original container, do not freeze, and avoid shaking the vial. Inspect for particulate matter before use and discard if the solution appears discolored or compromised.

The solution is given intravenously, typically via a controlled infusion pump or gravity drip. Administration rate should be adjusted according to the patient’s hemodynamic response and monitored continuously by qualified medical staff.

Serious risks include anaphylactic reactions, pulmonary edema from rapid volume overload, coagulopathy, and acute renal impairment. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Patients with known hypersensitivity to human albumin or any component of the formulation should not receive the product. Caution is also advised in individuals with severe heart failure, uncontrolled hypertension, or active bleeding disorders where rapid volume expansion could be harmful.